DEF: Theriva Biologics Seeks Shareholder Approval for Expanded Equity Plan and Director Elections at 2025 Annual Meeting Amidst Continued Net Losses

Theriva Biologics, Inc. has issued its proxy statement for the 2025 Annual Meeting, proposing the election of four directors, ratification of its independent auditor, and a significant increase in its stock incentive plan shares to attract and retain talent, against a backdrop of substantial net losses and declining shareholder returns.

Summary

• The 2025 Annual Meeting of Stockholders for Theriva Biologics, Inc. will be held on August 29, 2025, at 3:30 p.m. local time, at the company's research and clinical development principal place of business in Barcelona, Spain.
• Shareholders will vote on five key proposals: the election of four director nominees, the ratification of BDO USA, P.C. as the independent registered public accounting firm for 2025, and an amendment to the 2020 Stock Incentive Plan to increase authorized shares from 2,500,000 to 4,500,000.
• Advisory votes will also be held on the compensation of named executive officers and the frequency of future advisory votes on executive compensation, with the Board recommending a three-year frequency.
• As of the Record Date, July 8, 2025, there were 9,059,232 shares of Common Stock issued and outstanding.
• The company reported a net loss of $25,653,000 for the year ended December 31, 2024, an increase from $18,349,000 in 2023 and $20,025,000 in 2022.
• Cumulative Total Shareholder Return (TSR) declined significantly, from $16.71 in 2022 to $15.80 in 2023, and further to $2.57 in 2024.
• Steven A. Shallcross, CEO and CFO, received a total compensation of $876,313 in 2024, down from $1,271,913 in 2023, with no option awards granted in 2024.
• The 'Compensation Actually Paid' to the PEO was negative in 2024 at $(2,578,408) and in 2022 at $(904,217), but positive in 2023 at $851,435.
• The proposed increase in the 2020 Stock Incentive Plan aims to attract, retain, and motivate employees, directors, and consultants, and to preserve cash.
• The company's Burn Rate was 0.03% in 2024, significantly lower than 13.63% in 2023 and 11.27% in 2022. Dilution was 47.40% in 2024, and Overhang was 3.31% in 2024.

Sentiment

Score: 4

Explanation: The document presents standard corporate governance proposals and a necessary equity plan expansion for talent retention, which are positive operational aspects. However, the underlying financial performance, characterized by increasing net losses and declining Total Shareholder Return, indicates significant challenges, leading to a cautious sentiment.

Positives

• The Board of Directors maintains an independent Chairman, reinforcing oversight of business and affairs.
• The company has adopted robust corporate governance policies, including a Code of Conduct, Code of Ethics for Financial Management, and an Anti-Hedging/Anti-Pledging Policy.
• The Audit Committee, composed of independent directors, oversees financial reporting, internal controls, and auditor independence.
• The Compensation Committee's philosophy aims to align executive compensation with stockholder interests through a balanced mix of cash and equity-based incentives.
• The proposed increase in the 2020 Stock Incentive Plan is intended to attract, retain, and motivate key personnel, which is crucial for a biotechnology company.
• The company's Burn Rate significantly decreased to 0.03% in 2024, indicating a lower rate of equity award grants relative to outstanding shares compared to previous years.

Negatives

• The company reported a substantial net loss of $25,653,000 in 2024, an increase from previous years, indicating ongoing financial challenges.
• Cumulative Total Shareholder Return (TSR) has shown a consistent decline over the past three years, from $16.71 in 2022 to $2.57 in 2024, reflecting poor stock performance.
• The 'Compensation Actually Paid' to the Principal Executive Officer (PEO) was negative in two out of the last three fiscal years, specifically $(2,578,408) in 2024 and $(904,217) in 2022.
• No option awards were granted to the Named Executive Officer in 2024, which could impact long-term incentive alignment for that year, although awards for 2024 services were granted in May 2025.
• The Dilution percentage increased significantly to 47.40% in 2024, up from 29.57% in 2023, indicating a higher potential for dilution from equity awards and available shares.

Risks

• The document refers to risk factors identified in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent quarterly reports on Form 10-Q, which the Compensation Committee considers in its executive compensation program design. However, no new specific risks are detailed within this proxy statement.

Future Outlook

The company aims to attract, retain, and motivate employees, directors, and consultants by increasing the number of shares available for issuance under its 2020 Stock Incentive Plan. This is seen as necessary to compete successfully for talented personnel and to preserve cash. The Board also recommends holding future advisory votes on executive compensation every three years, aligning with a longer-term view of compensation and typical equity award vesting periods.

Management Comments

• The Board of Directors believes that separating the positions of Chairman of the Board and Chief Executive Officer reinforces the independence of the Board in its oversight of the company's business and affairs.
• The Compensation Committee's philosophy is to deliver higher rewards for superior performance and consequences for underperformance, providing a balanced mix of cash and equity-based compensation that aligns both short and long-term interests of executives with stockholders.
• Management believes that the current number of shares available for issuance under the 2020 Plan is insufficient to meet needs for awards over the next 12 months and to compete for talented employees and consultants.
• The Board of Directors unanimously recommends voting FOR the election of all four director nominees, FOR the Auditor Ratification Proposal, FOR the 2020 Plan Increase Proposal, FOR the advisory approval of executive compensation, and FOR a three-year frequency for future advisory votes on executive compensation.

Industry Context

As a biotechnology company, Theriva Biologics operates in a highly competitive market for executive talent, where offering competitive compensation packages, including equity incentives, is crucial for attracting and retaining skilled employees and consultants. The company's focus on clinical development and research implies a long-term investment horizon, which is reflected in its preference for a three-year frequency for advisory votes on executive compensation to align with longer-term performance goals.

Comparison to Industry Standards

• The Compensation Committee engaged Meridian Compensation Partners, LLC to provide an executive compensation report in December 2023, informing its decisions on executive compensation.
• The Compensation Committee does not attempt to benchmark executive compensation against any specific level, range, or percentile of compensation paid at other companies, nor does it apply specific measures of internal or external pay equity.
• The company's compensation approach aims to remain competitive with the market, with individual Named Executive Officer compensation potentially falling at varying levels compared to market data based on corporate and individual performance and other factors.

Corporate Governance

Related Party Transactions

• MaryAnn Shallcross, wife of Steven Shallcross (CEO and CFO), is employed as Director of Clinical Operations. Her compensation was $157,000 plus a $45,000 bonus in 2024. In 2023, her salary was $152,000 with a $70,000 bonus and 3,000 options granted. In 2022, her total compensation was less than $120,000 with 2,000 options granted.

Stakeholder Impact

• Shareholders: Will vote on key corporate governance matters, including director elections, auditor ratification, and executive compensation. The proposed increase in the stock incentive plan could lead to further dilution of existing shares.
• Employees, Directors, and Consultants: The proposed increase in the 2020 Stock Incentive Plan is intended to provide more equity awards, which serves as a crucial tool for attracting, retaining, and motivating these key personnel.
• Management: Executive compensation, including base salary, bonuses, and long-term incentives, is reviewed and approved by the Compensation Committee, with a focus on aligning performance with stockholder interests.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on August 29, 2025, to vote on the proposed matters.
• Announce voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K within four business days after the meeting.
• Continue to review and evaluate executive compensation programs and policies, considering input from stockholders, including through advisory votes on executive compensation.
• Hold the next advisory vote on the frequency of the Say-on-Pay vote at the 2031 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Theriva Biologics, Proxy Statement, SEC Filing, Annual Meeting, Stock Incentive Plan, Executive Compensation, Corporate Governance, Biotechnology, Shareholder Vote, Stock Options, Financial Performance, Net Loss, Total Shareholder Return, Director Election, Auditor Ratification